WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...
WuXi Biologics Launches a New GMP Commercial Drug Product Facility
* Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production * Increases up to 60 million vials for commercial drug production per year * Consolidates WuXi Biologics' pioneering the application of innovative technologies such as si...
WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility
- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...
WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date
* Successfully completed 12 regulatory inspections so far this year WUXI, China, Sept. 1, 2021 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received the Manufacturing License fromJapan'...
WuXi Biologics Reports Strong 2021 Interim Results
* Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million * Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million * Adjusted Net Profit Attributable to Owners of the Company Increases by 163.0% Y-o-Y toRMB1,768.7 Million * Gross and Net Profit Margins Reach 52.1% and 42.7%, Respectively ...
WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate
SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, it has once again received a European Medicines Agency (EMA) GMP c...
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
* First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system * Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed" LEVERKUSEN, Germany, July 26, 2021 /PRNewswire/ -- WuXi Biologics (...
WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates
WUXI, China and DAEJEON, South Korea, June 10, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS,"LCB"), today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnershi...
WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership
SHANGHAI and ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered ...
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
WUXI, China, May 14, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint venture company named WuXi XDC was established to provide end-to-end ...
WuXi Biologics Completed Three Acquisitions to Enhance its Global Network
SHANGHAI, May 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facility in Wuppertal,Germany, the Pfizer China ("Pfizer") manufacturing...
WuXi Biologics Receives 2021 Asia-Pacific Bioprocessing Excellence Award from IMAPAC
SHANGHAI, April 13, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized as the grand winner of the Bioprocessing Excellence inGreater China Region Award in two prestigious cate...
WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA
WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). T...
2020 Results Record High Despite a Challenging Year
Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2% Milestone Revenue Surged by 71.7% to US$95 Million Total Backlog up 122.0% to ...
WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group
SUZHOU, China, March 18, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other compani...
WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China
HANGZHOU, China, March 17, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has entered into an equity agreement with Pfizer China ("Pfizer") to acquire its state-of-the-art biologics manu...
WuXi Vaccines Achieves Weather-Tight Construction Milestone on Main Building of Manufacturing Facility Despite COVID-19
SHANGHAI and DUNDALK, Ireland, March 16, 2021 /PRNewswire/ -- WuXi Vaccines, a world-leading vaccine Contract Development and Manufacturing Organization (CDMO), today announced it achieved the weather-tight construction milestone of its vaccine manufacturing facility currently under construction ...
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility
WUXI, China, March 3, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the European Medicines Agency (EMA) has completed a remote Pre-Approval Inspection (PAI) on its drug substance facility ...
WuXi Biologics Wins 2021 CMO Leadership Awards in All Six Core Categories
SHANGHAI, Feb. 25, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the company has been named a winner of the 2021 CMO Leadership Awards for a fourth year in a row. The company is proud to ...
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
* Greatly increase the company's current capacity to 90,000L and enable WuXi Biologics to initiate any project within four weeks * Offer flexible large-scale manufacturing services by implementing Scale-out strategy WUXI, China, Feb. 9, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.H...
